Why Have the Hot Biotechs of a Year Ago Cooled Down?
This article was originally published in Start Up
Executive Summary
Most hot technologies have tended to fall into one of three categories: (i) incremental improvements that address a single segment of the drug discovery process but that fail to actually increase the number of clinical candidates produced by the drug discovery apparatus when considered as a whole; (ii) spellbinding technologies that have yet to show a practical, proven application to drug discovery; and (iii) technologies that are useful but that can't seem to be packaged within a successful corporate business model.